Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the Company will be making two presentations at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Disease, which is taking place from March 28 through April 1, 2023, in Gothenburg, Sweden.
The first presentation will discuss the Company's development plan for Parkinson's (PD) and Alzheimer's disease (AD), and the second presentation will show how mouse data fully predicts human outcome in improving function in AD and PD.
Dr. Maria Maccecchini, Chief Executive Officer of Annovis Bio, commented: "AD/PD 2023 provides an important global forum for thought leaders in neurodegenerative disease to discuss some of the most promising development-stage therapies for the treatment of Alzheimer's and Parkinson's disease. Given its unique ability to inhibit the production of multiple neurotoxic proteins, we believe our lead candidate, buntanetap, is well positioned to address both of these large and underserved patient populations, and we look forward to presenting updates for our two programs at this year's meeting."
Dr. Cheng Fang will present on the Company's development plans for buntanetap in both AD and PD in a presentation titled "Phase 3 Clinical Studies in Alzheimer's and Parkinson's Diseases: Interim Analysis of the Parkinson's Clinical Study". Dr. Fang's presentation will cover the study designs of the current Phase 2/3 study in Alzheimer's disease and the Phase 3 study in Parkinson's disease, as well as the interim analysis of the Parkinson's Disease study that includes results from 30% of patients who have received 2 months of treatment. Dr. Feng will also show the planned development to NDA.
Additionally, Dr. Maria Maccecchini will combine and compare old data in mice and new data in humans to show that mouse and rat data are predictive of human outcomes. In the presentation, titled "Do Mouse Data Lie? For Buntanetap They Totally Predict Human Outcome", data from the AD mice, Down Syndrome mice, PD mice, two Phase 1/2 double-blind, placebo-controlled human AD studies and one Phase 2 PD study will be compared to show the consistency on buntanetap's mechanism of action, the reversal of the toxic cascade and the resulting efficacy in AD and PD mice and humans.
Details on the Company's two presentations are provided below.
Abstract Number: 3080
Title: Phase 3 Clinical Studies in Alzheimer's and Parkinson's Disease; Interim Analysis of the Parkinson's Clinical Study
Date: Thursday, March 30, 2023
Presenter: Cheng Fang, Ph.D.
Abstract Number: 3114
Title: Do Mouse Data Lie? For Buntanetap They Totally Predict Human Outcome
Date: Friday, March 31, 2023
Presenter: Maria Maccecchini, Ph.D.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.